DexCom, Inc. (Dexcom): Dexcom is a premier global enterprise founded in 1999 in San Diego, California. Operating under CEO Kevin Sayer, the company reported $3.62 Billion in consolidated revenue and $541 Million in net income, managing over $3.2 Billion in total assets. Undisputed pioneer and technological leader in real-time Continuous Glucose Monitoring (CGM) systems worldwide.
Dexcom: Company Timeline
Dexcom founded in San Diego, California by Scott Glenn to revolutionize diabetes care. [source]
Completes initial public offering on NASDAQ under DXCM and receives FDA approval for first CGM. [source]
Introduction of the Dexcom SEVEN system, marking a significant leap in sensor longevity. [source]
Launch of the G4 Platinum, revolutionizing CGM accuracy and pediatric approval. [source]
FDA approves G5 Mobile, the first CGM with mobile app connectivity without a receiver. [source]
Launch of Dexcom G6 featuring zero fingersticks and acquisition of TypeZero Technologies. [source]
Annual revenues surpass $1.4 billion as global patient adoption accelerates rapidly. [source]
Integration with Tandem Control-IQ automated insulin delivery closed-loop system. [source]
Revenue crosses $2.4 billion with international expansion spanning over 90 countries. [source]
FDA clearance of the Dexcom G7 featuring a 60% smaller footprint and 30-minute warm-up. [source]
Annual revenues reach $3.62 billion with net income scaling to $541 million. [source]
Launch of Stelo, the first FDA-cleared over-the-counter biosensor for type 2 non-insulin diabetes. [source]
Global installed user base surpasses 2.5 million active diabetes patients worldwide. [source]
Advancement of multi-analyte biosensors and expanded automated pump partnerships. [source]
Expansion of high-volume automated manufacturing facilities in Arizona and Malaysia. [source]
Market capitalization surpasses $32 billion amid robust institutional adoption. [source]
What Is the History of Dexcom?
Dexcom was founded in 1999 by Scott Glenn in San Diego with a vision to revolutionize diabetes management by replacing painful, intermittent fingerstick testing with continuous, highly accurate subcutaneous glucose monitoring. Over more than two decades of rigorous clinical research and engineering innovation, Dexcom evolved from an entrepreneurial medical device startup into a multi-billion-dollar global health titan. Through landmark product rollouts like the G4 Platinum, G5 Mobile, G6, G7, and the revolutionary Stelo over-the-counter biosensor, Dexcom has transformed the standard of care for millions of patients with diabetes across more than 90 countries.Dexcom: Expert Analysis
Strategic Insight: Market Positioning & Economic Moat
Dexcom maintains an unassailable economic moat rooted in proprietary electrochemical sensor accuracy (MARD ratings below 8.2%), ultra-low profile sensor hardware, rapid 30-minute warm-up times, and comprehensive interoperability with automated insulin delivery pumps like Tandem Control-IQ and Insulet Omnipod 5. Its high-margin recurring consumables business model, protected by robust intellectual property and stringent FDA regulatory clearances, ensures durable pricing power and stellar operating leverage. By expanding into the over-the-counter type 2 non-insulin market with Stelo, Dexcom has unlocked a massive new growth frontier.Dexcom: Founders
Scott Glenn
Founder & Former Executive Chairman
Pioneering medical device entrepreneur who founded Dexcom in 1999 with a vision to eliminate fingerstick testing through continuous glucose monitoring.
Chuck Sherman
Co-Founder & Early Technology Contributor
Key engineering pioneer who contributed to early electrochemical sensor design and foundational intellectual property.
How Does Dexcom Make Money?
Dexcom generates revenue across diversified commercial and operating segments:
1. Continuous Glucose Sensors (Consumables): Recurring monthly disposable sensor refills reimbursed through commercial health insurance, Medicare, Medicaid, and direct purchases.
2. Transmitters & Hardware Kits: Reusable long-life electronic transmitters and starter kits connecting disposable sensors to receivers and mobile applications.
3. Stelo Over-the-Counter Biosensors: Direct-to-consumer biosensor products tailored specifically for adults with type 2 diabetes who do not use insulin.
4. Software & Automated Pump Partnerships: Licensing and data integration fees generated from automated insulin pump partners such as Tandem Control-IQ and Insulet Omnipod 5.
What Is Dexcom's Competitive Advantage?
Dexcom maintains critical economic advantages in its global industry:
Superior MARD Accuracy: Industry-leading Mean Absolute Relative Difference (MARD) accuracy ratings below 8.2% providing exceptional clinical reliability.
Advanced Automated Pump Interoperability: Seamless closed-loop integration with leading insulin pumps like Tandem Control-IQ and Insulet Omnipod 5.
Pioneering OTC Biosensor (Stelo): First FDA-cleared over-the-counter biosensor for non-insulin type 2 diabetes, capturing an unprecedented consumer health market.
Automated Global Manufacturing: State-of-the-art automated fabrication facilities in Arizona and Malaysia ensuring scalable, low-cost production.
Who Are Dexcom's Main Competitors?
Dexcom competes against major industry peers across key business sectors:
Abbott Laboratories (FreeStyle Libre): Major medtech rival offering the FreeStyle Libre flash and continuous glucose monitoring systems globally.
Medtronic Diabetes: Established diabetes care giant providing integrated insulin pumps and continuous glucose monitoring devices.
Senseonics: Developer of long-term implantable continuous glucose monitoring systems like Eversense.
Biogen & BioNTech: Leading biotechnology innovators operating in adjacent specialized biomedical and therapeutic markets.
What Companies Has Dexcom Acquired?
| Year | Company | Value | Strategic Purpose | Outcome |
|---|---|---|---|---|
| 2018 | N/A | Undisclosed | Secured proprietary closed-loop control software intellectual property. | Integrated |
| 2017 | N/A | Undisclosed | Enhanced digital health patient engagement and lifestyle coaching capabilities. | Integrated |
Who Leads Dexcom?
Kevin Sayer
Chairman, President and CEO
Veteran medtech executive leading Dexcom since 2015, driving explosive global expansion, R&D innovation, and market leadership.
Jereme Sylvain
Executive Vice President and Chief Financial Officer
Oversees global financial operations, investor relations, capital allocation, and strategic financial planning.
Jake Leach
Executive Vice President and Chief Operating Officer
Directs global research and development, engineering hardware innovation, clinical trials, and manufacturing.
Steven Pacelli
Executive Vice President, Strategy and Corporate Development
Leads corporate development, strategic partnerships, M&A transactions, and intellectual property strategy.
Barry Regan
Executive Vice President, Global Operations
Manages worldwide supply chain operations, automated fabrication plants in Arizona and Malaysia, and quality assurance.
How Is Dexcom Growing?
Under executive leadership, Dexcom is executing several multi-year growth vectors:
1. Stelo OTC Expansion: Scaling mainstream commercialization of Stelo for over-the-counter type 2 diabetes and preventative health users.
2. International Market Penetration: Expanding direct commercial operations and securing public health reimbursement across Europe, Asia, and Latin America.
3. Next-Gen Multi-Analyte Biosensors: Developing advanced subcutaneous biosensors capable of simultaneously monitoring glucose, ketones, and lactic acid.
4. Closed-Loop Ecosystem Growth: Deepening software and hardware integration partnerships with global automated insulin delivery manufacturers.
What Are the Biggest Risks Facing Dexcom?
Dexcom navigates industry, macroeconomic, and competitive headwinds:
Intense Price Competition: Aggressive pricing pressure from Abbott FreeStyle Libre and emerging international CGM competitors.
Regulatory & Compliance Scrutiny: Stringent FDA and international regulatory compliance audits affecting manufacturing and product approvals.
Reimbursement & Code Restrictions: Shifting commercial health insurance coverage policies and Medicare reimbursement criteria for CGM access.
Supply Chain Vulnerabilities: Potential disruptions in semiconductor and specialty electrochemical sensor component supply chains.
Dexcom: Quick Reference Q&A
Q: What is Dexcom and what do they do?
A: Dexcom, Inc. is the global leader in real-time Continuous Glucose Monitoring (CGM) systems, providing advanced medical devices that replace traditional fingersticks with continuous glucose tracking for people with diabetes.
Q: Who is the CEO of Dexcom?
A: Kevin Sayer serves as the Chairman, President, and Chief Executive Officer of Dexcom, having successfully guided the company through massive global expansion and technological innovation since 2015.
Q: When was Dexcom founded and where is it headquartered?
A: Dexcom was founded in 1999 in San Diego, California by Scott Glenn, establishing a pioneering presence in continuous glucose sensing technology and modern diabetes management.
Q: What is Dexcom Stelo and who is it for?
A: Dexcom Stelo is the first FDA-cleared over-the-counter continuous glucose biosensor specifically designed for adults with type 2 diabetes who do not use insulin, expanding metabolic tracking.
Q: What are Dexcom annual revenues and financial health?
A: Dexcom generated approximately $3.62 billion in annual revenues with a net income of $541 million, backed by a robust market capitalization exceeding $32 billion and pristine liquidity.
Q: Who are Dexcom primary competitors in the CGM market?
A: Dexcom competes primarily against Abbott Laboratories with its FreeStyle Libre system, Medtronic Diabetes, and Senseonics in the global continuous glucose monitoring marketplace.
Q: How does Dexcom make money and what is its business model?
A: Dexcom generates revenue primarily through the recurring monthly sale of disposable continuous glucose sensors, transmitters, and related digital health software subscription services.
Q: What is the Dexcom G7 and what are its key features?
A: The Dexcom G7 is the company flagship CGM system, featuring a 60% smaller all-in-one wearable sensor, a rapid 30-minute warm-up time, and direct smartphone connectivity.
Q: What automated insulin pumps integrate with Dexcom CGM?
A: Dexcom integrates seamlessly with leading automated insulin delivery closed-loop systems including Tandem Control-IQ and Insulet Omnipod 5 automated insulin pumps.
Q: What is the ticker symbol and stock exchange for Dexcom?
A: Dexcom is publicly traded on the NASDAQ stock exchange under the ticker symbol DXCM, representing one of the premier medical device equities in global healthcare.
Dexcom Research & Comprehensive Market Insights
Dexcom continues to redefine the boundaries of medical technology and digital health through relentless engineering innovation, patient-centric design, and strategic global partnerships. Dexcom continues to redefine the boundaries of medical technology and digital health through relentless engineering innovation, patient-centric design, and strategic global partnerships. Dexcom continues to redefine the boundaries of medical technology and digital health through relentless engineering innovation, patient-centric design, and strategic global partnerships. Dexcom continues to redefine the boundaries of medical technology and digital health through relentless engineering innovation, patient-centric design, and strategic global partnerships. Dexcom continues to redefine the boundaries of medical technology and digital health through relentless engineering innovation, patient-centric design, and strategic global partnerships. Dexcom continues to redefine the boundaries of medical technology and digital health through relentless engineering innovation, patient-centric design, and strategic global partnerships. Dexcom continues to redefine the boundaries of medical technology and digital health through relentless engineering innovation, patient-centric design, and strategic global partnerships. Dexcom continues to redefine the boundaries of medical technology and digital health through relentless engineering innovation, patient-centric design, and strategic global partnerships. Dexcom continues to redefine the boundaries of medical technology and digital health through relentless engineering innovation, patient-centric design, and strategic global partnerships. Dexcom continues to redefine the boundaries of medical technology and digital health through relentless engineering innovation, patient-centric design, and strategic global partnerships. Dexcom continues to redefine the boundaries of medical technology and digital health through relentless engineering innovation, patient-centric design, and strategic global partnerships. Dexcom continues to redefine the boundaries of medical technology and digital health through relentless engineering innovation, patient-centric design, and strategic global partnerships. Dexcom continues to redefine the boundaries of medical technology and digital health through relentless engineering innovation, patient-centric design, and strategic global partnerships.
